stockrowAdaptive Biotechnologies Corporation
ADPT Healthcare Diagnostics & Research
Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024.
- Revenue
- −10.7%
- EPS
- −66.7%
- Free cash flow
- +201.9%
Quarter to September 2026, against a year earlier
Follow ADPT
Alert me
Adaptive Biotechnologies Corporation (ADPT) Total debt
Adaptive Biotechnologies Corporation's total debt at the end of fiscal 2022 was $224.0M, up 109.3% from $107.0M in fiscal 2021. At the end of the quarter to 30 June 2026 it was $334.9M. Over the past ten years it has ranged from $36.6M (fiscal 2019) to $562.0M (fiscal 2017); the current reading is higher than 67% of that period. Adaptive Biotechnologies Corporation ranks 20th of 46 Diagnostics & Research companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $224.0M | 109.35% |
| FY2021 | $107.0M | 2.88% |
| FY2020 | $104.0M | 184.10% |
| FY2019 | $36.6M | (93.47%) |
| FY2018 | $561.0M | (0.18%) |
| FY2017 | $562.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $334.9M | 53.22% |
| Sep 2023 | $218.6M | (1.70%) |
| Jun 2023 | $222.3M | (0.52%) |
| Mar 2023 | $223.5M | (0.28%) |
| 14 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| SHC Sotera Health Company compare | $2.2B |
| RDNT RadNet, Inc. compare | $1.3B |
| NEO NeoGenomics, Inc. compare | $378.8M |
| ADPT Adaptive Biotechnologies Corporation | $334.9M |
| WGS GeneDx Holdings Corp. compare | $96.8M |
| BLLN BillionToOne, Inc. compare | $89.1M |
| CDNA CareDx, Inc. compare | $35.2M |
| VCYT Veracyte, Inc. compare | $14.0M |
| GRAL GRAIL, Inc. compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on ADPT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement